First Time Loading...
K

Kidswell Bio Corporation
TSE:4584

Watchlist Manager
Kidswell Bio Corporation
TSE:4584
Watchlist
Price: 147 JPY Market Closed
Updated: Mar 29, 2024

Intrinsic Value

Kidswell Bio Corp. engages in the research and development of biopharmaceutical products. [ Read More ]

The intrinsic value of one Kidswell Bio Corporation stock under the Base Case scenario is 419.42 JPY. Compared to the current market price of 147 JPY, Kidswell Bio Corporation is Undervalued by 65%.

Key Points:
Intrinsic Value
Base Case
419.42 JPY
Undervaluation 65%
Intrinsic Value
Price
K
Worst Case
Base Case
Best Case

Valuation Backtest
Kidswell Bio Corporation

Backtest Kidswell Bio Corporation Intrinsic Value
Dive into the past to invest in the future

Run backtest to discover the historical profit from buying and selling Kidswell Bio Corporation stocks based on their intrinsic value.

Analyze the historical link between intrinsic value and market price to make more informed investment decisions.

Run Backtest
Settings
Valuation Methods
Buy/Sell Thresholds
Buy When:
%
Sell When:
%
B
S
Run Backtest
How does it work?

Fundamental Analysis

Financials

Balance Sheet Decomposition
Kidswell Bio Corporation

Current Assets 5B
Cash & Short-Term Investments 2.2B
Receivables 481.9m
Other Current Assets 2.4B
Non-Current Assets 161.7m
PP&E 1.4m
Intangibles 1.7m
Other Non-Current Assets 158.6m
Current Liabilities 2B
Accounts Payable 72.3m
Other Current Liabilities 1.9B
Non-Current Liabilities 1.8B
Long-Term Debt 1.7B
Other Non-Current Liabilities 41.6m
Efficiency

Earnings Waterfall
Kidswell Bio Corporation

Revenue
2.6B JPY
Cost of Revenue
-1.3B JPY
Gross Profit
1.3B JPY
Operating Expenses
-2.4B JPY
Operating Income
-1.1B JPY
Other Expenses
-127.5m JPY
Net Income
-1.2B JPY

Free Cash Flow Analysis
Kidswell Bio Corporation

Last Value
3-Years Average
FCF Margin
Conversion Rate
History
Components
Chart
Table
What is Free Cash Flow?
Fundamental Scores

Profitability Score
Profitability Due Diligence

Kidswell Bio Corporation's profitability score is 28/100. The higher the profitability score, the more profitable the company is.

Positive Gross Profit
Exceptional 3-Years Revenue Growth
ROIC is Increasing
Exceptional 1-Year Revenue Growth
28/100
Profitability
Score

Kidswell Bio Corporation's profitability score is 28/100. The higher the profitability score, the more profitable the company is.

Solvency Score
Solvency Due Diligence

Kidswell Bio Corporation's solvency score is 34/100. The higher the solvency score, the more solvent the company is.

Short-Term Solvency
Negative Net Debt
Long-Term Solvency
Average D/E
34/100
Solvency
Score

Kidswell Bio Corporation's solvency score is 34/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

Price Targets Summary
Kidswell Bio Corporation

Wall Street analysts forecast Kidswell Bio Corporation stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for Kidswell Bio Corporation is 816 JPY with a low forecast of 808 JPY and a high forecast of 840 JPY.

Lowest
Price Target
808 JPY
450% Upside
Average
Price Target
816 JPY
455% Upside
Highest
Price Target
840 JPY
471% Upside
View Analyst Estimates
View Analyst Estimates

Competitive Landscape

Shareholder Return

Price
Kidswell Bio Corporation

1M 1M
+7%
6M 6M
-22%
1Y 1Y
-40%
3Y 3Y
-70%
5Y 5Y
-83%
10Y 10Y
-72%
Annual Price Range
147
52w Low
121
52w High
268
Price Metrics
Average Annual Return -20.09%
Standard Deviation of Annual Returns 34.25%
Max Drawdown -88%
Shares Statistics
Market Capitalization 5.6B JPY
Shares Outstanding 37 817 307
Percentage of Shares Shorted
N/A

Return Decomposition
Main factors of price return

What is price return decomposition?

Company Profile

Kidswell Bio Corporation

Country

Japan

Industry

Biotechnology

Market Cap

5.6B JPY

Dividend Yield

0%

Description

Kidswell Bio Corp. engages in the research and development of biopharmaceutical products. The company is headquartered in Chuo-Ku, Tokyo-To and currently employs 39 full-time employees. The company went IPO on 2012-11-30. The biosimilar business is engaged in the research, development and provision of filgrastim biosimilar products and pegfilgrastim biosimilar products for cancer, darbepoetin alfa biosimilar products for renal diseases, and ranibizumab biosimilar products for eye diseases. The new biopharmaceutical business is engaged in the research and development of anti-RAMP2 antibodies for cancer and eye diseases, as well as new antibodies. The new biotechnology business is engaged in the development of regenerative medicine products that utilize intracardiac stem cells for pediatric congenital heart diseases, and regenerative medicine products that utilize dental pulp stem cells for cleft lip and palate and intestinal ganglion cell deficiency diseases, as well as the joint research business with universities.

Contact

TOKYO-TO
Chuo-Ku
3F, Kanayama Bldg., 1-2-12, Shinkawa
+81362228970.0
https://www.g-gts.com/

IPO

2012-11-30

Employees

39

Officers

President, CEO & Representative Director
Shinya Kurebayashi
Chief Scientific Officer
Yasuyuki Mitani
Chief Manufacturing Officer
Munechika Sakabe
Corporate Officer of Research & Development Division and Director
Masayuki Kawakami

See Also

Discover More
What is the Intrinsic Value of one Kidswell Bio Corporation stock?

The intrinsic value of one Kidswell Bio Corporation stock under the Base Case scenario is 419.42 JPY.

Is Kidswell Bio Corporation stock undervalued or overvalued?

Compared to the current market price of 147 JPY, Kidswell Bio Corporation is Undervalued by 65%.